PACLITAXEL, ALPELISIB, DOXORUBICIN HYDROCHLORIDE, OLAPARIB, ALPELISIB, OLAPARIB clinical trials

EPIK-O: A Phase III, multi-center, randomized (1:1), open-label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high-grade serous ovarian cancer

This study is looking at a new combination of two drugs, alpelisib and olaparib, for women with a specific type of advanced ovarian cancer that has come back or grown after previous treatment. It compares this combination to standard chemotherapy to see if it works better.